Literature DB >> 23986204

Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice.

Young-Eun Cho1, Aninda Basu, Anzhi Dai, Michael Heldak, Ayako Makino.   

Abstract

Endothelial cell (EC) dysfunction is implicated in cardiovascular diseases, including diabetes. The decrease in nitric oxide (NO) bioavailability is the hallmark of endothelial dysfunction, and it leads to attenuated vascular relaxation and atherosclerosis followed by a decrease in blood flow. In the heart, decreased coronary blood flow is responsible for insufficient oxygen supply to cardiomyocytes and, subsequently, increases the incidence of cardiac ischemia. In this study we investigate whether and how reactive oxygen species (ROS) in mitochondria contribute to coronary endothelial dysfunction in type 2 diabetic (T2D) mice. T2D was induced in mice by a high-fat diet combined with a single injection of low-dose streptozotocin. ACh-induced vascular relaxation was significantly attenuated in coronary arteries (CAs) from T2D mice compared with controls. The pharmacological approach reveals that NO-dependent, but not hyperpolarization- or prostacyclin-dependent, relaxation was decreased in CAs from T2D mice. Attenuated ACh-induced relaxation in CAs from T2D mice was restored toward control level by treatment with mitoTempol (a mitochondria-specific O2(-) scavenger). Coronary ECs isolated from T2D mice exhibited a significant increase in mitochondrial ROS concentration and decrease in SOD2 protein expression compared with coronary ECs isolated from control mice. Furthermore, protein ubiquitination of SOD2 was significantly increased in coronary ECs isolated from T2D mice. These results suggest that augmented SOD2 ubiquitination leads to the increase in mitochondrial ROS concentration in coronary ECs from T2D mice and attenuates coronary vascular relaxation in T2D mice.

Entities:  

Keywords:  diabetic vascular complication; hyperglycemia; posttranslational modification; ubiquitin-proteasome system

Mesh:

Substances:

Year:  2013        PMID: 23986204      PMCID: PMC3840199          DOI: 10.1152/ajpcell.00234.2013

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  88 in total

Review 1.  Mechanisms of metabolic coronary flow regulation.

Authors:  Andreas Deussen; Vahagn Ohanyan; Anett Jannasch; Liya Yin; William Chilian
Journal:  J Mol Cell Cardiol       Date:  2011-10-08       Impact factor: 5.000

Review 2.  Oxidative stress-mediated regulation of proteasome complexes.

Authors:  Charity T Aiken; Robyn M Kaake; Xiaorong Wang; Lan Huang
Journal:  Mol Cell Proteomics       Date:  2011-05       Impact factor: 5.911

Review 3.  Diabetes mellitus and vascular endothelial dysfunction: current perspectives.

Authors:  Dimitris Tousoulis; Anna-Maria Kampoli; Christodoulos Stefanadis
Journal:  Curr Vasc Pharmacol       Date:  2012-01       Impact factor: 2.719

Review 4.  Reactive oxygen species and endothelial function in diabetes.

Authors:  Zahra Fatehi-Hassanabad; Catherine B Chan; Brian L Furman
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes.

Authors:  J Y Youn; L Gao; H Cai
Journal:  Diabetologia       Date:  2012-05-02       Impact factor: 10.122

6.  Nongenetic mouse models of non-insulin-dependent diabetes mellitus.

Authors:  J Luo; J Quan; J Tsai; C K Hobensack; C Sullivan; R Hector; G M Reaven
Journal:  Metabolism       Date:  1998-06       Impact factor: 8.694

Review 7.  Endothelium-derived hyperpolarizing factor: where are we now?

Authors:  Michel Félétou; Paul M Vanhoutte
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-03-16       Impact factor: 8.311

Review 8.  Endothelial dysfunction in coronary artery disease.

Authors:  T F Lüscher; F C Tanner; M R Tschudi; G Noll
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

9.  β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency.

Authors:  Safia Costes; Chang-jiang Huang; Tatyana Gurlo; Marie Daval; Aleksey V Matveyenko; Robert A Rizza; Alexandra E Butler; Peter C Butler
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

10.  The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.

Authors:  Min Shen; Dongdong Sun; Weijie Li; Bing Liu; Shenxu Wang; Zheng Zhang; Feng Cao
Journal:  Exp Diabetes Res       Date:  2012-03-15
View more
  35 in total

1.  Astragalus polysaccharide suppresses palmitate-induced apoptosis in human cardiac myocytes: the role of Nrf1 and antioxidant response.

Authors:  Ji Zhang; Jian-Yun Gu; Zhi-Song Chen; Kai-Chen Xing; Bing Sun
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Coronary microvascular disease as an early culprit in the pathophysiology of diabetes and metabolic syndrome.

Authors:  Hicham Labazi; Aaron J Trask
Journal:  Pharmacol Res       Date:  2017-07-09       Impact factor: 7.658

3.  Overexpression of hexokinase 2 reduces mitochondrial calcium overload in coronary endothelial cells of type 2 diabetic mice.

Authors:  Minglin Pan; Ying Han; Aninda Basu; Anzhi Dai; Rui Si; Conor Willson; Angela Balistrieri; Brian T Scott; Ayako Makino
Journal:  Am J Physiol Cell Physiol       Date:  2018-03-07       Impact factor: 4.249

4.  Akt2 (Protein Kinase B Beta) Stabilizes ATP7A, a Copper Transporter for Extracellular Superoxide Dismutase, in Vascular Smooth Muscle: Novel Mechanism to Limit Endothelial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Varadarajan Sudhahar; Mustafa Nazir Okur; Zsolt Bagi; John P O'Bryan; Nissim Hay; Ayako Makino; Vijay S Patel; Shane A Phillips; David Stepp; Masuko Ushio-Fukai; Tohru Fukai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-04       Impact factor: 8.311

5.  Overexpressing superoxide dismutase 2 induces a supernormal cardiac function by enhancing redox-dependent mitochondrial function and metabolic dilation.

Authors:  Patrick T Kang; Chwen-Lih Chen; Vahagn Ohanyan; Daniel J Luther; J Gary Meszaros; William M Chilian; Yeong-Renn Chen
Journal:  J Mol Cell Cardiol       Date:  2015-09-12       Impact factor: 5.000

Review 6.  Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?

Authors:  Ying Wang; Ira Tabas
Journal:  J Atheroscler Thromb       Date:  2014-04-08       Impact factor: 4.928

7.  A key mediator, PTX3, of IKK/IκB/NF-κB exacerbates human umbilical vein endothelial cell injury and dysfunction.

Authors:  Yongbo Zhao; Guangxing Feng; Yanzhi Wang; Yuehong Yue; Weichao Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 8.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

9.  SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.

Authors:  Ying Han; Young-Eun Cho; Ramon Ayon; Rui Guo; Katia D Youssef; Minglin Pan; Anzhi Dai; Jason X-J Yuan; Ayako Makino
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-11       Impact factor: 5.464

10.  Endothelial HIF-2α contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition.

Authors:  Haiyang Tang; Aleksandra Babicheva; Kimberly M McDermott; Yali Gu; Ramon J Ayon; Shanshan Song; Ziyi Wang; Akash Gupta; Tong Zhou; Xutong Sun; Swetaleena Dash; Zilu Wang; Angela Balistrieri; Qiuyu Zheng; Arlette G Cordery; Ankit A Desai; Franz Rischard; Zain Khalpey; Jian Wang; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-10-26       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.